Ampio Pharmaceuticals Inc (AMPE) Drops 5.18% on February 11

Equities Staff |

Ampio Pharmaceuticals Inc (AMPE) was one of the Russell 2000's biggest losers for Thursday February 11 as the stock slid 5.18% to $1.83, a loss of $-0.1 per share. Starting at an opening price of $2.06 a share, the stock traded between $1.69 and $2.06 over the course of the trading day. Volume was 148,493 shares over 604 trades, against an average daily volume of 216,233 shares and a total float of 52 million.

The losses send Ampio Pharmaceuticals Inc down to a market cap of $95.16 million. In the last year, Ampio Pharmaceuticals Inc has traded between $9.01 and $1.81, and its 50-day SMA is currently $2.86 and 200-day SMA is $2.83.

Ampio Pharmaceuticals Inc is a biopharmaceutical company engaged in developing innovative, proprietary pharmaceutical drugs and diagnostic products to identify, treat and prevent human diseases including metabolic disorders, cancer etc.

Ampio Pharmaceuticals Inc is based out of Englewood, CO and has some 23 employees. Its CEO is Michael Macaluso.

For a complete fundamental analysis analysis of Ampio Pharmaceuticals Inc, check out’s Stock Valuation Analysis report for AMPE. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Breathtec BioMedical Inc.

Breathtec Biomedical Inc is a medical diagnostics company. It is engaged in developing & commercializing breath analysis devices for the early detection of infections & life threatening diseases including cancers,…

Private Markets


Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…


Wealthfront is an automated investment service that serves as an alternative to traditional financial advisory services. The company manages a diversified, continually rebalanced portfolio of index funds on their clients’…